Clinical trials: Invasive Bladder Cancer, open to volunteers
Superficial Bladder Cancer, Bladder Cancer
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index…
- Trial name
- TROJAN (NCT03379909)
- Testing
- Metformin
- Where
- 3 sites in Netherlands
- Volunteers
- 49 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NMIBC
Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall.
- Trial name
- HIGCrecur (NCT06889623)
- Testing
- Immediate postoperative chemotherapy
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Changhai Hospital
Bladder Cancer, Urinary Bladder Neoplasms
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the…
- Trial name
- NCT07222488
- Testing
- MK-3120
- Where
- 17 sites in United States, Austria and 10 more
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer, Invasive Breast Cancer
CONFIRM: Magnetic Resonance Guided Radiation Therapy
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer.
- Conditions
- Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma
- Trial name
- CONFIRM (NCT04368702)
- Testing
- Viewray MRIdian® Linac
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Brigham and Women's Hospital
Non Muscle Invasive Bladder Cancer
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
This study is a prospective, randomized, multicenter clinical trial aiming to enroll 428 patients with non-muscle-invasive bladder cancer (NMIBC) from the Department of Urology at Jiangsu Provincial People's Hospital and its…
- Trial name
- NCT07036731
- Testing
- Urine biomarker -Guided without reTURBT
- Where
- China
- Volunteers
- 428 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual…
- Conditions
- Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma
- Trial name
- INSITE (NCT06396533)
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Fox Chase Cancer Center
Urinary Bladder Neoplasms, BCG Vaccine
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Previous studies have reported the efficacy of Bacillus Calmette-Guérin (BCG) combined with other drugs for the treatment of bladder cancer.
- Conditions
- Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active, Multicenter Study
- Trial name
- NCT06441110
- Testing
- Tislelizumab in Combination with Bacillus Calmette-Guérin
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fujian Medical University Union Hospital
Bladder Cancer, Non-muscle Invasive Bladder Cancer
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
Blue light cystoscopy (BLC) is a diagnostic procedure in bladder cancer where the inside of the bladder is observed with a camera to detect bladder lesions.
- Trial name
- ENAiBLE (NCT07144319)
- Where
- 12 sites in United States, Belgium and 3 more
- Volunteers
- 500 people
- Sponsor
- Photocure
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
This study investigates the feasibility of the Labcorp Plasma Detect, which is an assay (test) that looks for circulating tumor DNA (ctDNA) in patients who have muscle-invasive (MI) urothelial carcinoma (also known as MI bladder…
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT07726602
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- OHSU Knight Cancer Institute
High-risk NMIBC
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
The study is to evaluate the safety and tolerability of SHR-1501 alone or in combination with BCG or SHR-1316 in the patients with NMIBC, and to determine the RP2D of SHR-1501 in combination with BCG or SHR-1316.
- Trial name
- NCT05410730
- Testing
- SHR-1501
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Non Muscle Invasive Bladder Cancer
Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT
This is a prospective, open-label, single-center, single-arm phase II clinical study to evaluate the efficacy and safety of toripalimab combined with intravesical gemcitabine as adjuvant therapy in patients with high-risk…
- Trial name
- NCT07808216
- Testing
- Toripalimab (JS001 ), Gemcitabine (GEM)
- Volunteers
- 54 people
- Sponsor
- Tianjin First Central Hospital
Bladder Cancer, Liquid Biopsy
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder cancers and is characterized by a high risk of recurrence and progression.
- Conditions
- Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
- Trial name
- NCT07187635
- Testing
- Second Transurethral Resection of Bladder Tumor (re-TURBT), utDNA Testing (Urine Tumor DNA Detection)
- Where
- 7 sites in China
- Volunteers
- 196 people
- Sponsor
- Tianjin Medical University Second Hospital
Bladder Cancer, Non Muscle Invasive
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine the safety and tolerability of intravesical BH011 in patients with high-risk non-muscle invasive bladder cancer（NMIBC） after Bacillus Calmette-Guerin（BCG） failure and to assess the…
- Trial name
- NCT06732531
- Testing
- BH011
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Zhuhai Beihai Biotech Co., Ltd
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer (NMIBC)
A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer
The goal of this clinical trial is to learn if the drug Alpha1H works to treat low-to-intermediate risk non-muscle-invasive bladder cancer in adults. It will also learn about the safety of drug Alpha1H.
- Trial name
- NCT07804056
- Testing
- Alpha1H, Transurethral Resection of Bladder Tumor (TURBT), Intravesical Chemotherapy
- Where
- Czechia
- Volunteers
- 194 people
- Sponsor
- Hamlet Pharma AB
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of…
- Conditions
- Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- GAIN-BCG (NCT07000084)
- Testing
- BCG Solution, Biopsy of Bladder, Cystoscopy
- Where
- 60 sites in United States
- Volunteers
- 330 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bladder (Urothelial, Transitional Cell) Cancer
An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer
The goal of this exploratory study is to evaluate the safety and efficacy of nimotuzumab combined with chemoradiotherapy in bladder - preserving treatment for MIBC patients who are ineligible for or decline radical cystectomy.
- Trial name
- NCT07053735
- Testing
- Nimotuzumab and Radiotherapy
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
This study is an open, single-arm, single-center exploratory clinical study to explore the efficacy and safety of Disitamab Vedotin (RC-48) in combination with radiotherapy for the treatment of patients with HER2-expressing…
- Trial name
- NCT07100184
- Testing
- Disitamab Vedotin combined with Radiotherapy
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Muscle-Invasive Bladder Cancer (MIBC)
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
The purpose of this Phase II, open-label, multicenter, randomized controlled study is to evaluate the efficacy and safety of Enfortumab Vedotin in combination with Toripalimab compared to Gemcitabine plus Cisplatin.
- Trial name
- NCT07647289
- Testing
- enfortumab vedotin (EV), Toripalimab, Gemcitabine (Chemotherapy)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Peking University Third Hospital
Bladder Cancer
Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool
Multicenter, observational, prospective, biological pilot study on liquid biopsy, aimed at investigating methylation profiles in relation to the early diagnosis of bladder cancer, to validate the potential of commercially…
- Trial name
- NCT06878027
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute